Helfried Metzler
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Helfried Metzler has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
Kurt Huber
2 shared publicationsSibylle Kozek-Langenecker
2 shared publicationsA. Münch
Medizinische Universitat Graz
1 shared publicationK. Huber
Wilhelminenspital
1 shared publicationM.N. Vicenzi
Medizinische Universitat Graz
1 shared publicationS. Kozek-Langenecker
Medizinische Universität Wien
1 shared publication
Latest Publications
- 1 March 2008
- Published by Elsevier in Best Practice & Research Clinical Anaesthesiology
- Vol. 22 (1) , 81-94
Antiplatelet therapy and coronary stents in perioperative medicine – the two sides of the coin
- 1 March 2008
- Published by Elsevier in Best Practice & Research Clinical Anaesthesiology
- Vol. 22 (1) , 81-94
Antiplatelet therapy and coronary stents in perioperative medicine – the two sides of the coin
- 1 February 2008
- Published by Wolters Kluwer Health in Current Opinion in Anaesthesiology
- Vol. 21 (1) , 55-59
Anaesthesia in patients with drug-eluting stents
The management of patients with recent coronary artery stents presenting for noncardiac surgery has become a major topic of interest and concern for all perioperative caregivers. This review will update recent reports and particularly new guidelines as well as recommendations. Based on the available literature all experts recommend avoiding premature discontinuation of antiplatelet drug therapy if possible except for a few surgical procedures. Drug-eluting stents obviously carry more risks than bare-metal stents. Anaesthesiologists may understand the specific problem of drug-eluting stents, the recent debate among cardiologists and the implications for the perioperative scenario.
- 1 February 2008
- Published by Wolters Kluwer Health in Current Opinion in Anaesthesiology
- Vol. 21 (1) , 55-59
Anaesthesia in patients with drug-eluting stents
The management of patients with recent coronary artery stents presenting for noncardiac surgery has become a major topic of interest and concern for all perioperative caregivers. This review will update recent reports and particularly new guidelines as well as recommendations. Based on the available literature all experts recommend avoiding premature discontinuation of antiplatelet drug therapy if possible except for a few surgical procedures. Drug-eluting stents obviously carry more risks than bare-metal stents. Anaesthesiologists may understand the specific problem of drug-eluting stents, the recent debate among cardiologists and the implications for the perioperative scenario.
- 1 April 2007
- Published by Springer Nature in Der Anaesthesist
- Vol. 56 (4) , 401-412
Koronare Stents, duale Antiplättchentherapie und die perioperative Problematik
Bei perkutaner koronarer Intervention werden in bis zu 90% der Fälle Koronarstents implantiert. Sie erfordern typabhängig eine duale Antiplättchentherapie (Clopidogrel und Acetylsalicylsäure). Die Therapiedauer liegt bei 3–4 Wochen bzw. 6–12 Monaten bei Bare-Metal- bzw. Drug-Eluting-Stents. Absetzen der dualen Antiplättchentherapie erhöht das Risiko einer Stentthrombose, ihre Weiterführung das einer relevanten Blutung im Operationsgebiet. Das perioperative Vorgehen stützt sich auf Empfehlungen anästhesiologischer und kardiologischer Gesellschaften. Bei Eingriffen mit hohem Blutungsrisiko kann von chirurgischer Seite ein Absetzen beider Substanzen erforderlich sein, bei hohem Thromboserisiko sollten beide Medikamente, zumindest aber Acetylsalicylsäure, bis zum Operationstag gegeben werden. Für die Durchführung einer Regionalanästhesie existieren Empfehlungen von nationalen Gesellschaften. Patienten, die nach koronarer Stentimplantation unter dualer Antiplättchentherapie stehen, profitieren von einer interdisziplinären Betreuung durch Anästhesiologen, Operateur und Kardiologen. Up to 90% of all percutaneous coronary interventions include coronary artery stenting. Dual antiplatelet therapy, usually involving acetylsalicyl acid combined with clopidogrel, is mandatory for patients with coronary artery stents. The duration of antiplatelet therapy for bare metal stents is 3–4 weeks, for drug eluting stents 6–12 months. Preoperative discontinuation of both drugs increases the risk of stent thrombosis, continuation the risk of relevant bleeding. According to the recommendations of anaesthesiological and cardiological societies, perioperative management has to balance the risk of bleeding vs stent thrombosis. Surgery involving a high risk of bleeding can require the discontinuance of both substances. In cases of high thrombosis risk, at least the acetylsalicyl acid should be continued until the day of surgery. For patients under antiplatelet therapy scheduled for local anaesthesia, national recommendations exist. A close collaboration between the anaesthesiologist, cardiologist and surgeon is essential for appropriate pre-, intra- and postoperative management.
- 1 April 2007
- Published by Springer Nature in Der Anaesthesist
- Vol. 56 (4) , 401-412
Koronare Stents, duale Antiplättchentherapie und die perioperative Problematik
Bei perkutaner koronarer Intervention werden in bis zu 90% der Fälle Koronarstents implantiert. Sie erfordern typabhängig eine duale Antiplättchentherapie (Clopidogrel und Acetylsalicylsäure). Die Therapiedauer liegt bei 3–4 Wochen bzw. 6–12 Monaten bei Bare-Metal- bzw. Drug-Eluting-Stents. Absetzen der dualen Antiplättchentherapie erhöht das Risiko einer Stentthrombose, ihre Weiterführung das einer relevanten Blutung im Operationsgebiet. Das perioperative Vorgehen stützt sich auf Empfehlungen anästhesiologischer und kardiologischer Gesellschaften. Bei Eingriffen mit hohem Blutungsrisiko kann von chirurgischer Seite ein Absetzen beider Substanzen erforderlich sein, bei hohem Thromboserisiko sollten beide Medikamente, zumindest aber Acetylsalicylsäure, bis zum Operationstag gegeben werden. Für die Durchführung einer Regionalanästhesie existieren Empfehlungen von nationalen Gesellschaften. Patienten, die nach koronarer Stentimplantation unter dualer Antiplättchentherapie stehen, profitieren von einer interdisziplinären Betreuung durch Anästhesiologen, Operateur und Kardiologen. Up to 90% of all percutaneous coronary interventions include coronary artery stenting. Dual antiplatelet therapy, usually involving acetylsalicyl acid combined with clopidogrel, is mandatory for patients with coronary artery stents. The duration of antiplatelet therapy for bare metal stents is 3–4 weeks, for drug eluting stents 6–12 months. Preoperative discontinuation of both drugs increases the risk of stent thrombosis, continuation the risk of relevant bleeding. According to the recommendations of anaesthesiological and cardiological societies, perioperative management has to balance the risk of bleeding vs stent thrombosis. Surgery involving a high risk of bleeding can require the discontinuance of both substances. In cases of high thrombosis risk, at least the acetylsalicyl acid should be continued until the day of surgery. For patients under antiplatelet therapy scheduled for local anaesthesia, national recommendations exist. A close collaboration between the anaesthesiologist, cardiologist and surgeon is essential for appropriate pre-, intra- and postoperative management.